LLY stock forecast valuation scenarios see potential to hit $900 in 12 months if revenue surprises continue, supported by strong clinical trial momentum. In May, Eli Lilly announced the results of its Phase 3b SURMOUNT-5 trial, wherein Zepbound (tirzepatide) outperformed Novo Nordisk’s Wegovy (semaglutide) in helping adults with obesity or overweight achieve significant weight loss. Over 72 weeks, participants on Zepbound lost an average of 20.2% of their body weight compared to 13.7% on Wegovy, a 47% greater relative reduction. Zepbound also outperformed on all critical secondary endpoints, cementing its place as the top treatment option in the obesity drug market. Eli Lilly & Co has witnessed significant sales activity from Lilly Endowment Inc , a major shareholder. The endowment sold 113,694 shares for $86,792,716, followed by additional sales of 215,822 shares for $177,289,555, 135,193 shares for $107,362,359, and 112,596 shares for $92,502,494. These massive transactions underscore the endowment’s strategic decision to reduce its stake in the pharmaceutical giant, potentially reallocating resources to other ventures or causes. Smart money indicators in LLY stock forecast reports show large-scale block trades accumulating positions over $805, reflecting confidence in continued upward trajectory.